3-10-2017 – Health & Medicine, Press release from: TMR
Lateral lumbar interbody fusion (LLIF) is a minimally invasive technique and is in demand for surgical spinal fusion procedure. LLIF is an effective and safe surgical procedure that makes post-operative recovery quicker and less painful. The incision is made from the side through psoas muscle that allows surgeons to access more surface area with less damage to the tissue and reduced blood loss.
Lateral lumbar interbody fusion is a surgical procedure used to treat specific types of disorders of lumbar spine, such as degenerative disc disease, low grade spondylolisthesis, degenerative scoliosis (asymmetric disc degeneration) and deformity, and some recurrent lumbar herniated disc and lumbar stenosis. Developments in magnification and illumination associated with surgical instrumentation have led to increased applicability of minimally invasive technique for spinal fusion. High device cost and various procedure levels are likely to boost the growth of the market.
Obtain Report Details @www.transparencymarketresearch.com/lateral-lumbar-interbo…
The minimally invasive lateral lumbar interbody fusion has certain advantages such as enhanced spine alignment and easier spine access in several cases such as degenerative diseases and correction in sagittal and coronal deformities. Large number of surgeons prefer this procedure, as it results in less blood loss and lower damage to the tissues around the surgical area. Reduced time for operation and length of hospital stay, greater fusion, and lesser infection rates are the other advantages of this procedure.
Increased incidence of degenerative diseases and rising prevalence of lower back pain in the population above 45 years drive the global lateral lumbar interbody fusion market. Higher visualization resulting in easy and precise operation with less tissue sparing practice are other factors that propel the global lateral lumbar interbody fusion market. However, high cost of operation and risks associated with lateral lumbar interbody fusion such as psoas muscles or neural network injury and bone graft fusion complication restrain the market.
